Melanoma incidence has increased in the last 30 years and over 800,000 people have a previous diagnosis of melanoma in the US. Melanoma has a high likelihood to metastasize (spread to other parts of the body) and accounts for 80% of the skin cancer-related deaths. As a result, many melanoma survivors constantly fear when their cancers might come back and spread. Currently, there is no active means to prevent tumor recurrence and metastasis for melanoma survivors. Evidence strongly suggests that inflammation is associated with unfavorable clinical prognosis such as tumor progression and recurrence. We have found that human metastatic melanoma cells show a special form of inflammatory response called autoinflammation because of constant activation of a unique inflammatory platform called inflammasome. This autoinflammation is mediated by IL-1?, a pro-inflammatory cytokine inducing a large portfolio of genes. EGCG is an active ingredient in green tea and has many biological effects including anti-cancer, anti-inflammatory, and anti-pathogen properties. Because many inflammatory mediators reported to be inhibited by EGCG are controlled by active IL-1? (secreted form), we hypothesized that EGCG might inhibit IL-1? activation, thereby controlling other mediators that are important for tumor progression and metastasis. We indeed found that a practical and physiologically achievable dose of EGCG (1 M) suppresses IL-1? secretion in human metastatic melanoma cells that carry a feature of autoinflammation. We propose to explore the molecular mechanisms of action of a practical dose of EGCG in regulating IL-1? activation in human metastatic melanoma in vitro, and analyze the effects of EGCG on a tumor cell population [putative cancer stem cell (CSC) population] that has a high tendency to initiate tumor formation and recurrence. We also propose to study the biological effects of EGCG on melanoma recurrence using a spontaneous metastasis model in vivo. We will use patient-derived tumor xenograft (PDX) model (avatar model), one of the best models in human cancer research that recapitulates complex tumor microenvironment. We will also use cells from a genetically engineered mouse (GEM) model of metastasizing melanoma. PDX and GEM tumor cells will be labeled with a modified labeling method with enhanced brightness, high detection sensitivity, high transduction efficiency and stable labeling. State-of-the-art multimodality imaging will be used to longitudinally monitor tumor recurrence at the initial tumor site, lymph nodes and distant metastatic sites. Tumor cells will be examined to define the effects of EGCG on IL-1? pathway, CSC traits, and epithelial-mesenchymal transition. Because IL-1? plays a critical role in tumor progression, such studies will elucidate the mechanisms of action of EGCG on regulating dysregulated cytokines in cancers and will lead to the development of effective chemopreventive agents with limited to no toxicity that can be taken by cancer survivors to control tumor recurrence and prolong their lives.

Public Health Relevance

Melanoma accounts for 80% of the skin cancer-related deaths, but there is no active means to prevent the recurrence of melanoma. EGCG is an active ingredient in green tea and may be an effective chemopreventive agent for tumor recurrence because it inhibits a unique inflammatory response called autoinflammation in human metastatic melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA197919-01A1
Application #
9106608
Study Section
Chemo/Dietary Prevention Study Section (CDP)
Program Officer
Seifried, Harold E
Project Start
2016-03-01
Project End
2021-02-28
Budget Start
2016-03-01
Budget End
2017-02-28
Support Year
1
Fiscal Year
2016
Total Cost
$355,706
Indirect Cost
$126,956
Name
University of Colorado Denver
Department
Dermatology
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Sarvi, Sana; Crispin, Richard; Lu, Yuting et al. (2018) ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells. Cell Chem Biol 25:1456-1469.e6
Ravindran Menon, Dinoop; Luo, Yuchun; Arcaroli, John J et al. (2018) CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. Cancer Res 78:6561-6574
Pearson, David R; Fujita, Mayumi; High, Whitney A (2017) Fulminant Mycosis Fungoides with Tissue Eosinophilia: A Unique Presentation of Two Cases with Acro-Periorbital Ulceration and An Aggressive Clinical Course. J Mol Biomark Diagn 8:
Zhai, Z; Liu, W; Kaur, M et al. (2017) NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene 36:3820-3830